Table 1.
Patient Demographics and Baseline Characteristics
| Parameter | Lidocaine Patch 5% (n = 52) | Naproxen 500 mg Twice Daily (n = 48) |
|---|---|---|
| Mean age ± SD, yrs | 55.7 ± 16.0 | 51.5 ± 11.8 |
| Gender, n (%) | ||
| Male | 18 (34.6) | 7 (14.6) |
| Female | 34 (65.4) | 41 (85.4) |
| Race/Ethnicity, n (%) | ||
| White | 45 (86.5) | 36 (75.0) |
| Black | 5 (9.6) | 11 (22.9) |
| Hispanic | 2 (3.9) | 1 (2.1) |
| Presence of Select Concomitant Illnesses, n (%) | ||
| Allergy/Asthma | 23 (44.2) | 19 (39.6) |
| Cardiovascular | 15 (28.9) | 11 (22.9) |
| Dermatologic | 3 (5.8) | 0 |
| Diabetes | 5 (9.6) | 6 (12.5) |
| Gastrointestinal | 15 (28.9) | 9 (18.8) |
| Hepatobiliary | 2 (3.85) | 1 (2.1) |
| Musculoskeletal | 10 (19.2) | 11 (22.9) |
| Renal/Urologic | 3 (5.8) | 2 (4.2) |
| Other | 18 (34.6) | 16 (33.3) |
| Clinical Global Impression of Severity (mean ± SD) | 2.25 ± 0.59 | 2.29 ± 0.65 |
| Mild, n (%) | 4 (7.7) | 5 (10.4) |
| Moderate, n (%) | 31 (59.6) | 24 (50.0) |
| Severe, n (%) | 17 (32.7) | 19 (39.6) |
| Average pain intensity (mean ± SD) | 4.5 ± 2.5 | 4.9 ± 2.6 |